Patents by Inventor Paul J. Hergenrother

Paul J. Hergenrother has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160346277
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: July 26, 2016
    Publication date: December 1, 2016
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
  • Patent number: 9434736
    Abstract: The present invention, among other things, provides compounds, compositions and methods for treatment of cancer. In some embodiments, the present invention provides methods for treating blood cancer using agelastatin alkaloids.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: September 6, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Mohammad Movassaghi, Paul J. Hergenrother
  • Patent number: 9421202
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: August 23, 2016
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins University
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
  • Patent number: 9399035
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 26, 2016
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Patent number: 9382215
    Abstract: The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 5, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Steven C. Zimmerman, Chun-Ho Wong, Paul J. Hergenrother, Jessie Peh
  • Publication number: 20160176833
    Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 23, 2016
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Howard S. Roth
  • Patent number: 9353150
    Abstract: The present application provides, among other things, a compound of Formula I-a and/or I-b, or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification. The compounds of the invention are useful for treating various diseases including cancer.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 31, 2016
    Assignees: Massachusetts Institute of Technology, The Board of Trustees of the University of Illinois
    Inventors: Mohammad Movassaghi, Justin Kim, Paul J. Hergenrother, Karen Morrison, Nicolas Boyer
  • Publication number: 20160122348
    Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Applicants: The Board of Trustees of the University of Illinois, The Board of Regents of the University of Texas System
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
  • Publication number: 20160030457
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 4, 2016
    Applicants: The Board of Regents of the University of Texas System, The Board of Trustees of University of Illinois
    Inventors: Paul J. HERGENROTHER, David A. BOOTHMAN, Joseph S. BAIR, Lifen CAO, Jinming GAO, Xiumei HUANG, Xiuquan LUO, Xinpeng MA, Zachary R. MOORE, Elizabeth I. PARKINSON
  • Patent number: 9249116
    Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: February 2, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Howard S. Roth
  • Patent number: 9233960
    Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 12, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson
  • Publication number: 20150344452
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: August 10, 2015
    Publication date: December 3, 2015
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Publication number: 20150274638
    Abstract: The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.
    Type: Application
    Filed: March 25, 2013
    Publication date: October 1, 2015
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Robert W. Huigens, III, Karen C. Morrison, Robert W. Hicklin, II, Timothy A. Flood, JR.
  • Publication number: 20150231132
    Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    Type: Application
    Filed: December 23, 2014
    Publication date: August 20, 2015
    Inventor: Paul J. Hergenrother
  • Patent number: 9102661
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: August 11, 2015
    Assignee: The Board of Trustees of the University Illinois
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Publication number: 20150099759
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 4, 2013
    Publication date: April 9, 2015
    Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Theodore M. Tarasow
  • Publication number: 20150080405
    Abstract: The present invention, among other things, provides compounds, compositions and methods for treatment of cancer. In some embodiments, the present invention provides methods for treating blood cancer using agelastatin alkaloids.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 19, 2015
    Inventors: Mohammad Movassaghi, Paul J. Hergenrother
  • Publication number: 20150025083
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 22, 2015
    Applicants: THE JOHNS HOPKINS UNIVERSITY, VANQUISH ONCOLOGY, INC.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
  • Publication number: 20150017264
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 15, 2015
    Applicants: Vanquish Oncology, Inc., TheBoard of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Publication number: 20150011509
    Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 8, 2015
    Applicants: The Board of Trustees of the University of Illnois, The Board of Regents of the University of Texas System
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Rahul Palchaudhuri, Elizabeth I. Parkinson